AIFM2 and melanoma: To further validate the clinical relevance of our findings, we analyzed a tissue microarray (TMA) comprising 111 tumor samples from melanoma patients to assess the expression of SLC25A1, ACLY, and FSP1 using multiplex immunofluorescence (mIF) staining.